UnicoCell Biomed Co., Ltd.
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; CDMO; UnicoVial, a cryogenic vial for the storage of cel… Read more
UnicoCell Biomed Co., Ltd. (6794) - Net Assets
Latest net assets as of June 2025: NT$750.50 Million TWD
Based on the latest financial reports, UnicoCell Biomed Co., Ltd. (6794) has net assets worth NT$750.50 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$832.20 Million) and total liabilities (NT$81.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$750.50 Million |
| % of Total Assets | 90.18% |
| Annual Growth Rate | 25.79% |
| 5-Year Change | 99.36% |
| 10-Year Change | N/A |
| Growth Volatility | 39.36 |
UnicoCell Biomed Co., Ltd. - Net Assets Trend (2017–2024)
This chart illustrates how UnicoCell Biomed Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for UnicoCell Biomed Co., Ltd. (2017–2024)
The table below shows the annual net assets of UnicoCell Biomed Co., Ltd. from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$684.61 Million | +14.78% |
| 2023-12-31 | NT$596.44 Million | +78.65% |
| 2022-12-31 | NT$333.85 Million | +26.94% |
| 2021-12-31 | NT$263.00 Million | -23.41% |
| 2020-12-31 | NT$343.41 Million | +16.68% |
| 2019-12-31 | NT$294.32 Million | +7.82% |
| 2018-12-31 | NT$272.98 Million | +98.78% |
| 2017-12-31 | NT$137.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to UnicoCell Biomed Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 60536500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$584.11 Million | 85.32% |
| Other Components | NT$705.87 Million | 103.10% |
| Total Equity | NT$684.61 Million | 100.00% |
UnicoCell Biomed Co., Ltd. Competitors by Market Cap
The table below lists competitors of UnicoCell Biomed Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zenix Robotics Co.,Ltd
KQ:381620
|
$52.13 Million |
|
Alpha Technology Group Limited Ordinary Shares
NASDAQ:ATGL
|
$52.14 Million |
|
Korea Parts & Fasteners Co.Ltd
KQ:024880
|
$52.16 Million |
|
Betmakers Technology Group Ltd
PINK:TPBTF
|
$52.16 Million |
|
Insights Analytics Bhd
KLSE:0376
|
$52.09 Million |
|
Global View Co Ltd
TW:3040
|
$52.08 Million |
|
Big Shopping Centers Ltd
TA:BIG
|
$52.08 Million |
|
Tamil Nadu Newsprint & Papers Limited
NSE:TNPL
|
$52.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in UnicoCell Biomed Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 596,442,000 to 684,608,000, a change of 88,166,000 (14.8%).
- Net loss of 93,072,000 reduced equity.
- New share issuances of 179,850,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-93.07 Million | -13.59% |
| Share Issuances | NT$179.85 Million | +26.27% |
| Other Changes | NT$1.39 Million | +0.2% |
| Total Change | NT$- | 14.78% |
Book Value vs Market Value Analysis
This analysis compares UnicoCell Biomed Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 6.35x to 6.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$12.60 | NT$80.00 | x |
| 2018-12-31 | NT$16.90 | NT$80.00 | x |
| 2019-12-31 | NT$9.62 | NT$80.00 | x |
| 2020-12-31 | NT$9.60 | NT$80.00 | x |
| 2021-12-31 | NT$6.98 | NT$80.00 | x |
| 2022-12-31 | NT$8.05 | NT$80.00 | x |
| 2023-12-31 | NT$11.06 | NT$80.00 | x |
| 2024-12-31 | NT$11.54 | NT$80.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently UnicoCell Biomed Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -291.94%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.14x
- Recent ROE (-13.59%) is above the historical average (-25.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -31.26% | -717.07% | 0.04x | 1.03x | NT$-56.66 Million |
| 2018 | -14.84% | -737.58% | 0.02x | 1.05x | NT$-67.81 Million |
| 2019 | -34.30% | -641.41% | 0.04x | 1.21x | NT$-130.37 Million |
| 2020 | -31.80% | -2742.57% | 0.01x | 1.14x | NT$-143.55 Million |
| 2021 | -32.84% | -1056.30% | 0.03x | 1.13x | NT$-112.67 Million |
| 2022 | -27.30% | -633.15% | 0.03x | 1.24x | NT$-124.54 Million |
| 2023 | -14.10% | -342.06% | 0.04x | 1.15x | NT$-143.75 Million |
| 2024 | -13.59% | -291.94% | 0.04x | 1.14x | NT$-161.53 Million |
Industry Comparison
This section compares UnicoCell Biomed Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| UnicoCell Biomed Co., Ltd. (6794) | NT$750.50 Million | -31.26% | 0.11x | $52.11 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |